Research Article
Prevalence of Anxiety and Depression in Prostate Cancer Patients and Their Spouses: An Unaddressed Reality
Table 1
General characteristics of the population.
| | Mean/median | Range/SD |
| | Age | | Patients () | 70.71/71 | 49–92/8.3 | | Spouses () | 68.3/68 | 45–87/7.9 |
| | Time since diagnosis (months): | 33.3/18 | 2–142/34.27 |
| | PSA (ng/ml) | 2.88/0.1 | 0–88/12.18 |
| | VAS | 0.42/0 | 0–2/0.54 | | VAS 0: (60.9%) | | VAS 1: (36.4%) | | VAS 2: (2.7%) |
| | Patient education level | Spouse education level | | Elementary: (53.8%) | Elementary: (64.2%) | | High school: (37%) | High school (27%) | | University: (9.2%) | University: (8.8%) |
| | Comorbidities: | None: 40 (21.7%) | | Cormob 1: 58 (31.5%) | | Comorb 2: 64 (34.9%) | | Mean: 1.36 | Comorb 3 or more: 22 (11.9%) | | Median: 1 |
| | Stage () | | Localized (63.7%) | | L. advanced (17.9%) | | MTX (13%) | | CRPC (5.4%) |
| | Primary treatment () | Time since diagnosis (months): | | AS (; 10.9%) | 33.29 (median: 18), range: 2–142 | | RP (: 53.8%) | 55.9 (median: 48), range: 11–132 | | RT (: 8.7%) | 30.5 (median: 18), range: 2–142 | | HT (: 26.6%) | 12.8 (median: 12), range: 2–28 | | ST: (22.3%) | 39.8 (median: 23), range: 3–138 |
|
|
MTX: metastatic; CRPC: Castrate-resistant prostate cancer. AS: active surveillance; RP: radical prostatectomy; RT: radiotherapy; HT: hormone therapy; ST: sequential treatment. |
